Bionik Laboratories (BNKL) 10-Q 13 Feb 18 2018 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Dec. 31, 2017	Feb. 13, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Entity Registrant Name	Bionik Laboratories Corp.
Entity Central Index Key	1,508,381
Current Fiscal Year End Date	--03-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	BNKL
Entity Common Stock, Shares Outstanding		55,885,279

Condensed Consolidated Interim

Condensed Consolidated Interim Balance Sheets - USD ($)	Dec. 31, 2017	Mar. 31, 2017
Current
Cash and cash equivalents	$ 998,661	$ 543,650
Accounts receivable, net of allowance for doubtful accounts of $16,349 (March 31, 2017 - $10,000)	306,572	383,903
Prepaid expenses and other receivables (Note 5)	145,044	228,047
Inventories (Note 6)	302,414	228,249
Due from related parties (Note 9(a))	19,374	18,731
Total Current Assets	1,772,065	1,402,580
Equipment (Note 7)	174,997	227,421
Technology and other assets (Note 4)	4,783,704	5,030,624
Goodwill (Note 4)	22,308,275	22,308,275
Total Assets	29,039,041	28,968,900
Current
Accounts Payable (Notes 9(b))	794,875	784,771
Accrued liabilities (Notes 3, 8 and 9(b))	1,868,225	1,228,657
Customer advances	800	121,562
Demand Notes Payable (Note 8(a))	50,000	330,600
Promissory Notes payable (Note 8(b))	0	236,548
Convertible Loans Payable (Note 8(d), (e) and (f))	7,079,852	2,017,488
Short term loan (Note 8(c))	400,000	0
Deferred revenue	113,801	98,624
Total Current Liabilities	10,307,553	4,818,250
Shareholders’ Equity
Common Shares, par value $0.001; Authorized - 250,000,000 (March 31, 2017 - 150,000,000); Issued and outstanding 55,885,279 and 45,909,336 Exchangeable Shares (March 31, 2017 - 48,885,107 and 47,909,336 Exchangeable Shares) (Note 10)	101,794	96,794
Additional paid in capital	48,081,670	45,088,171
Shares to be issued (Note 10)	60,000	0
Deficit	(29,554,125)	(21,076,464)
Accumulated other comprehensive income	42,149	42,149
Total Shareholders’ Equity	18,731,488	24,150,650
Total Liabilities and Shareholders’ Equity	29,039,041	28,968,900
Special Voting Preferred Stock [Member]
Shareholders’ Equity
Preferred Stock, par value $0.001; Authorized 10,000,000 Special Voting Preferred Stock, par value $0.001; Authorized; Issued and outstanding - 1 (March 31, 2017 - 1)	$ 0	$ 0

Condensed Consolidated Interim3

Condensed Consolidated Interim Balance Sheets [Parenthetical] - USD ($)	Dec. 31, 2017	Mar. 31, 2017
Allowance for Doubtful Accounts Receivable, Current	$ 16,349	$ 10,000
Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Common Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Common Stock, Shares Authorized	250,000,000	150,000,000
Common Stock, Shares, Issued	55,885,279	48,885,107
Common Stock, Shares, Outstanding	55,885,279	48,885,107
Common Stock, Other Shares, Outstanding	45,909,336	47,909,336
Special Voting Preferred Stock [Member]
Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001
Preferred Stock, Shares Issued	1	1
Preferred Stock, Shares Outstanding	1	1

Condensed Consolidated Interim4

Condensed Consolidated Interim Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Sales	$ 260,960	$ 372,426	$ 570,327	$ 553,900
Cost of Sales	88,357	334,786	177,482	405,680
Gross Margin	172,603	37,640	392,845	148,220
Operating expenses
Sales and marketing	432,260	377,046	1,313,077	646,509
Research and development	546,350	571,671	1,947,659	1,803,234
General and administrative	783,784	409,669	2,916,917	2,291,136
Share compensation expense (Note 11)	271,001	227,540	1,284,257	651,630
Convertible debt accretion (Note 8)	216,302	0	290,375	0
Amortization (Note 4)	76,985	0	246,920	0
Depreciation (Note 7)	21,234	24,028	69,606	57,781
Total operating expenses	2,347,916	1,609,954	8,068,811	5,450,290
Other expenses (income)
Foreign Exchange	(11,485)	0	102,671	0
Interest expense (Note 8)	416,990	13,808	657,350	23,839
Other income	(59)	(4,363)	649	(410,877)
Total other expenses (income)	405,446	9,445	760,670	(387,038)
Net loss and comprehensive loss for the period	$ (2,580,759)	$ (1,581,759)	$ (8,436,636)	$ (4,915,032)
Loss per share - basic	$ (0.03)	$ (0.02)	$ (0.08)	$ (0.05)
Loss per share - diluted	$ (0.03)	$ (0.02)	$ (0.08)	$ (0.05)
Weighted average number of shares outstanding - basic	101,794,615	96,362,541	99,335,514	90,286,864
Weighted average number of shares outstanding - diluted	101,794,615	96,362,541	99,335,514	90,286,864

Condensed Consolidated Interim5

Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Deficiency) - USD ($)	Total	Special Voting Preferred Stock [Member]	Common Stock [Member]	[1]	Additional Paid-in Capital [Member]	Shares To Be Issued [Member]	Deficit [Member]	Comprehensive Income [Member]
Opening Balance at Mar. 31, 2016	$ 5,399,851	$ 0	$ 72,591		$ 18,292,173	$ 0	$ (13,007,062)	$ 42,149
Opening Balance (in shares) at Mar. 31, 2016		1	72,591,292
Shares issued to acquire IMT	23,177,000	$ 0	$ 23,650		23,153,350	0	0	0
Shares issued to acquire IMT (in shares)		0	23,650,000
Share compensation acquired	2,582,890	$ 0	$ 0		2,582,890	0	0	0
Options exercised	18,166	$ 0	$ 110		18,056	0	0	0
Options exercised (in shares)		0	110,096
Cashless exercise of warrants	0	$ 0	$ 51		(51)	0	0	0
Cashless exercise of warrants (in shares)		0	51,249
Warrants exercised	40,195	$ 0	$ 175		40,020	0	0	0
Warrants exercised (in shares)		0	174,759
Share compensation expense	1,001,950	$ 0	$ 217		1,001,733	0	0	0
Share compensation expense (in shares)		0	217,047
Net loss for the period	(8,069,402)	$ 0	$ 0		0	0	(8,069,402)	0
Closing Balance at Mar. 31, 2017	24,150,650	$ 0	$ 96,794		45,088,171	0	(21,076,464)	42,149
Closing Balance (in shares) at Mar. 31, 2017		1	96,794,443
Warrants exercised	1,125,038	$ 0	$ 5,000		1,120,038	0	0	0
Warrants exercised (in shares)		0	5,000,172
Share compensation expense	1,284,257	$ 0	$ 0		1,284,257	0	0	0
Share compensation expense (in shares)		0	0
Fair value of warrants on convertible loans	548,179	$ 0	$ 0		548,179	0	0	0
Warrant down round feature (Note 12)	0	0	0		41,025	0	(41,025)	0
Shares to be issued	60,000	$ 0	$ 0		0	60,000	0	0
Shares to be issued (in shares)		0	0
Net loss for the period	(8,436,636)	$ 0	$ 0		0	0	(8,436,636)	0
Closing Balance at Dec. 31, 2017	$ 18,731,488	$ 0	$ 101,794		$ 48,081,670	$ 60,000	$ (29,544,125)	$ 42,149
Closing Balance (in shares) at Dec. 31, 2017		1	101,794,615
[1]	Includes exchangeable shares

Condensed Consolidated Interim6

Condensed Consolidated Interim Statements of Cash Flows - USD ($)	1 Months Ended	9 Months Ended
	Apr. 21, 2016	Dec. 31, 2017	Dec. 31, 2016
Operating activities
Net loss for the period		$ (8,436,636)	$ (4,915,032)
Adjustment for items not affecting cash
Depreciation		69,606	57,781
Amortization		246,920	0
Interest expense		640,168	23,839
Share based compensation expense		1,284,257	592,130
Convertible debt accretion		290,375	0
Shares issued for services		60,000	59,500
Allowance for doubtful accounts		(16,349)	0
Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities		(5,861,659)	(4,181,782)
Changes in non-cash working capital items
Accounts receivable		93,680	(247,359)
Prepaid expenses and other receivables		83,003	95,562
Due from related parties		(643)	532
Inventories		(74,165)	(120,894)
Accounts payable		10,104	(720,573)
Accrued liabilities		639,568	(492,047)
Customer advances		(120,762)	28,000
Deferred revenue		15,177	97,615
Net cash used in operating activities		(5,215,697)	(5,540,946)
Investing activities
Acquisition of equipment		(17,182)	(9,827)
Net cash used in investing activities		(17,182)	(9,827)
Financing activities
Proceeds from convertible loans		4,699,975	483,333
Proceeds on exercise of warrants		1,125,038	0
Repayment of Promissory note principal		(200,000)	0
Repayment of Promissory note interest		(49,505)	0
Repayment of Demand notes principal		(208,359)	0
Repayment of Demand notes interest		(79,259)	0
Proceeds from short term loan		400,000	0
Cash acquired on acquisition		0	266,635
Net cash provided by financing activities		5,687,890	749,968
Net decrease in cash and cash equivalents for the period		455,011	(4,800,805)
Cash and cash equivalents, beginning of period	$ 5,381,757	543,650	5,381,757
Cash and cash equivalents, end of period		$ 998,661	$ 580,952
Assets acquired and liabilities assumed as at April 21, 2016:
Current assets, including cash of $266,635	478,843
Equipment	59,749
Intangible assets	5,580,704
Goodwill	22,308,275
Accounts payable	(241,299)
Accrued liabilities	(361,029)
Customer deposits	(86,487)
Demand notes payable	(324,894)
Promissory Notes payable	(217,808)
Bionik advance	(1,436,164)
Non-cash consideration	$ 25,759,890

Condensed Consolidated Interim7

Condensed Consolidated Interim Statements of Cash Flows [Parenthetical]	1 Months Ended
	Apr. 21, 2016USD ($)
Cash Acquired from Acquisition	$ 266,635

NATURE OF OPERATIONS AND GOING

NATURE OF OPERATIONS AND GOING CONCERN	9 Months Ended
	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	NATURE OF OPERATIONS AND GOING CONCERN The Company and its Operations Bionik Laboratories Corp. (the “Company” or “Bionik”) was incorporated on January 8, 2010 in the State of Colorado as Strategic Dental Management Corp. On July 16, 2013 the Company changed its name to Drywave Technologies Inc. (“Drywave”) and its state of incorporation from Colorado to Delaware. Effective February 13, 2015, the Company changed its name to Bionik Laboratories Corp. and reduced the authorized number of shares of common stock from 200,000,000 150,000,000 1-for-0.831105 On February 26, 2015, the Company entered into a Share Exchange Agreement and related transactions whereby it acquired Bionik Laboratories Inc., a Canadian Corporation (“Bionik Canada”). Bionik Canada issued 50,000,000 3.14 100 As a result of the shareholders of Bionik Canada having a controlling interest in the Company subsequent to the Merger, for accounting purposes the Merger does not constitute a business combination. The transaction has been accounted for as a recapitalization of the Company with Bionik Canada being the accounting acquirer even though the legal acquirer is Bionik, accordingly, the historic financial statements of Bionik Canada are presented as the comparative balances for the period prior to the Merger. References to the Company refer to the Company and its wholly owned subsidiaries, Bionik Acquisition Inc. and Bionik Canada. References to Drywave relate to the Company prior to the Merger. On April 21, 2016, the Company acquired all of the outstanding shares and, accordingly, all assets and liabilities of Interactive Motion Technologies, Inc. (“IMT”), a Boston, Massachusetts-based global pioneer and leader in providing effective robotic products for neurorehabilitation, pursuant to an Agreement and Plan of Merger (the “Merger Agreement”) dated March 1, 2016, with IMT, Hermano Igo Krebs, and Bionik Mergerco Inc., a Massachusetts corporation and the Company’s wholly owned subsidiary (“Bionik Mergeco”). The merger agreement provided for the merger of Bionik Mergerco with and into IMT, with IMT surviving the merger as the Company’s wholly owned subsidiary. In return for acquiring IMT, IMT shareholders received an aggregate of 23,650,000 Bionik Laboratories Corp. is a robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home. The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility impaired individuals, including three products in the market and four products in varying stages of development. The InMotion Systems - the InMotion ARM, In Motion Wrist, InMotion Hand – are designed to provide intelligent, adaptive therapy in a manner that has been clinically verified to maximize neuro-recovery. Bionik also has a lower-body exoskeleton - the ARKE - designed to allow paraplegics as well as other wheelchair users the ability to rehabilitate through walking. The Company is developing with a partner a lower body product based on some of the ARKE technology, which should allow certain individuals to walk better, who have limited mobility. This product is expected to be launched in the consumer home market. The unaudited condensed consolidated interim financial statements consolidate the Company and its wholly owned subsidiaries Bionik Canada, Bionik Acquisition Inc. and Bionik, Inc. (the former IMT) since its acquisition on April 21, 2016. These unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), which contemplates continuation of the Company as a going concern, which assumes the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company’s principal offices are located at 483 Bay Street, N105, Toronto, Ontario, Canada M5G 2C9 and its U.S. address is 80 Coolidge Hill Road, Watertown, MA. USA 02472. Going Concern As at December 31, 2017, the Company had a working capital deficit of $ 8,535,488 3,415,670 29,554,125 21,076,464 8,436,636 (4,915,032) There is no certainty that the Company will be successful in generating sufficient cash flow from operations or achieving and maintaining profitable operations in the future to enable it to meet its obligations as they come due and consequently continue as a going concern. The Company will require additional financing this year to fund its operations and it is currently working on securing this funding through the issuance of convertible promissory notes, corporate collaborations, public or private equity offerings or debt financings. Sales of additional equity or equity linked securities by the Company would result in the dilution of the interests of existing stockholders. There can be no assurance that financing will be available when required. In the event that the necessary additional financing is not obtained, the Company would reduce its discretionary overhead costs substantial or otherwise curtail operations. The Company expects the forgoing, or a combination thereof, to meet the Company’s anticipated cash requirements for the next 12 months; however, these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed consolidated interim financial statements do not include any adjustments to reflect the possible future effects on recoverability and reclassification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. The condensed consolidated interim financial statements do not include any adjustments related to the recoverability and classification of the recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. All adjustments, consisting only of normal recurring items, considered necessary for fair presentation have been included in these condensed consolidated interim financial statements.

CHANGE IN ACCOUNTING POLICY

CHANGE IN ACCOUNTING POLICY	9 Months Ended
	Dec. 31, 2017
Disclosure Text Block [Abstract]
Accounting Changes and Error Corrections [Text Block]	2. CHANGE IN ACCOUNTING POLICY The FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260) Distinguishing Liabilities From Equity (Topic 480) Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments With Down Round Features II Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests With a Scope Exception On consideration of the above factors, the Company elected to early adopt ASU 2017-11 on July 1, 2017, the ASU is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. For all other organizations, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. The early adoption allows the Company to reduce the cost and complexity of updating the fair value measurement each reporting period and eliminate the unnecessary volatility in reported earnings created by the revaluation when the Company’s shares’ value changes. The Company presented the change in accounting policy through the retrospective application of the new accounting principle to all prior periods, as described in ASU No. 250-10-45-5, Accounting Changes and Error Corrections. Income statement Three months period ended December Nine months period ended December As As originally Effect of originally Effect of reported As adjusted change reported As adjusted change Sales $ 372,426 $ 372,426 $ - $ 553,900 $ 553,900 $ - Cost of Sales 334,786 334,786 - 405,680 405,680 - Total operating expenses 1,609,954 1,609,954 - 5,450,290 5,450,290 - Total other expenses (761,896) 9,445 (771,341) (2,897,426) (387,038) 2,510,388 Net income (loss) and comprehensive loss for the period (810,418) (1,581,759) (771,341) (2,404,644) (4,915,032) (2,510,388) Net income (loss) per share (0.01) (0.02) (0.01) (0.03) (0.05) (0.02) Balance sheet As at March 31, 2017 As Effect of reported As adjusted change Current assets $ 1,402,580 $ 1,402,580 $ - Capital assets 227,421 227,421 - Intangible assets 27,338,899 27,338,899 - Total assets 28,968,900 28,968,900 - Warrant derivative liability 959,600 - (959,600) Other current liabilities 4,818,205 4,818,250 45 Total liabilities 5,777,805 4,818,250 (959,555) Common stock 96,794 96,794 - Additional paid in capital 38,640,706 45,088,171 6,447,465 Retained earnings (15,588,554) (21,076,464) (5,487,910) Accumulated other comprehensive income 42,149 42,149 - Total shareholders' equity 23,191,095 24,150,650 959,555 Total liabilities and shareholders' equity 28,968,900 29,968,900 - The change in retained earnings consists of a change in net loss for the year ended March 31 2017, changing from $ 3,936,574 8,069,402 4,132,828 5,487,910 Statement of cash flows As at December 31, 2016 As originally As adjusted Effect of Net loss for the period $ (2,404,644) $ (4,915,032) $ (2,510,388) Adjustment for items not affecting cash Depreciation 57,781 57,781 Interest expense 23,839 23,839 Share-based compensation expense 592,130 592,130 Shares issued for service 59,500 59,500 Change in fair value of warrant derivative liability (2,510,388) - 2,510,388 Change in non-cash working capital items (1,359,164) (1,359,164) Net cash used in operating activities (5,540,946) (5,540,946) - Net cash used in investing activities (9,827) (9,827) - Net cash provided by financing activities 749,968 749,968 - Net decrease in cash and cash equivalents for the period (4,800,805) (4,800,805) - Cash and cash equivalents, beginning of period 5,381,757 5,381,757 - Cash and cash equivalents, end of period 580,952 580,952 -

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	3. SIGNIFICANT ACCOUNTING POLICIES These unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual audited financial statements of the Company and should be read in conjunction with those annual audited financial statements filed on Form 10-K for the year ended March 31, 2017. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2017. For a public entity, early adoption is not permitted. The impact on the condensed consolidated interim financial statements of adopting ASU 2014-09 will be assessed by management. In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes,” which requires that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015-17 is effective for the fiscal year commencing after December 15, 2017. The Company does not anticipate that the adoption of ASU No. 2015-17 will have a material effect on the condensed consolidated interim financial position or the consolidated results of operations. In January 2016, the FASB issued ASU No. 2016-01 “Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities”. The updates makes several modifications to Subtopic 825-10, including the elimination of the available-for-sale classification of equity investments, and it requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in operations. The update is effective for fiscal years beginning after December 2017. The Company is still assessing the impact that the adoption of ASU 2016-01 will have on the condensed consolidated interim financial position and the consolidated results of operations. In February 2016, the FASB issued ASU 2016-02, “Leases”. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company is still assessing the impact that the adoption of ASU 2016-02 will have on the condensed consolidated interim financial position and the consolidated results of operations. In March 2016, the FASB issued ASU 2016-09, “Compensation – Stock Compensation: Improvements to Employee Share-Based Payment Accounting”. Several aspects of the accounting for share-based payment award transaction are simplified, including (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company has adopted this policy during the period and there was no impact on the condensed consolidated interim financial statements. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. This ASU provides eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for the fiscal year commencing after December 15, 2017. The Company is still assessing the impact that the adoption of ASU 2016-15 will have on the condensed consolidated interim statement of cash flows. In January 2017, the FASB issued ASU 2017-01, “Business Combinations: Clarifying the definition of a Business” which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU 2017-01 further states that when substantially all of the fair value of gross assets acquitted is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term “outputs” to be consistent with how it described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after June 30, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date. In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019. In September 2017, the FASB issued ASU 2017-13, “Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842)”. ASU 2017-13 amends the early adoption date option for certain companies related to the adoption of ASU 2014-09 and ASU 2016-02. The Company is not early adopting this standard; however, we are currently assessing the impact that the eventual adoption of this standard will have on the Company. The Company recognizes revenue from product sales when persuasive evidence of an agreement with customer exists, products are shipped or title passes pursuant to the terms of the agreement, the amount due from the customer is fixed or determinable, collectability is reasonably assured, and there are no significant future performance obligation. Deposits are carried as liabilities until the requirements for revenue recognition are met. The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the balance sheet and amounted to $ 64,957 15,355 30,732 The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction. ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expand disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs which are as observable as possible and the methods most applicable to the specific situation of each company or valued item. The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, other receivables, accounts payable and accrued liabilities, due from related parties, demand notes payable, promissory notes payable, convertible notes payable, and short-term loans approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company’s policy is to recognize transfers into and out of Level 3 as of the date of the event or change in the circumstances that caused the transfer. There were no such transfers during the period.

ACQUISITION

ACQUISITION	9 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	ACQUISITION On April 21, 2016, the Company acquired 100 23,650,000 Bionik also assumed each of the 3,895,000 3,000,000 1,000,000 0.25 1,000,000 0.95 1,000,000 1.05 2,582,890 As a result of the acquisition of IMT, the Company acquired assets including three licensed patents, two license agreements, three FDA listed products, an FDA inspected manufacturing facility, extensive clinical and sales data, and international distributors. The Company retained an independent valuator to determine the purchase price allocation, which reflects the allocation of assets and goodwill. As at April 21, 2016 $ Fair value of 23,650,000 shares of common stock (a) 23,177,000 Fair value of vested stock options (b) 2,582,890 Allocation of purchase price: 25,759,890 Cash and cash equivalents 266,635 Accounts receivable 6,490 Inventories 188,879 Prepaid expenses and other current assets 16,839 Equipment 59,749 Liabilities assumed: Accounts payable (241,299) Accrued liabilities (361,029) Customer deposits (86,487) Demand notes payable (324,894) Promissory notes payable (217,808) Bionik advance (c) (1,436,164) Net assets acquired (2,129,089) Patents and exclusive License Agreement 1,306,031 Trademark 2,505,907 Customer relationships 1,431,680 Non compete agreement 61,366 Assembled Workforce 275,720 Goodwill 22,308,275 25,759,890 (a) The fair value of common stock was based on $ 0.98 (b) The fair value of the vested stock options was determined using the Black Scholes option pricing model with the following key assumptions: a risk free rate of 1.59 0 114 (c) Included in the net assets acquired was a loan issued to IMT in the amount of $ 300,000 6 200,000 Amortization Value acquired Expense Value at 3 Months 9 Months Value at Intangible assets acquired period (years) $ $ $ $ $ $ Patents and exclusive License Agreement 9.74 1,306,031 126,375 1,179,656 33,522 100,604 1,079,052 Trademark Indefinite 2,505,907 - 2,505,907 - - 2,505,907 Customer relationships 10 1,431,680 134,931 1,296,749 35,792 107,414 1,189,335 Non compete agreement 2 61,366 28,918 32,448 7,671 23,038 9,410 Assembled Workforce 1 275,720 259,856 15,864 - 15,864 - 5,580,704 550,080 5,030,624 76,985 246,920 4,783,704

PREPAID EXPENSES AND OTHER RECE

PREPAID EXPENSES AND OTHER RECEIVABLES	9 Months Ended
	Dec. 31, 2017
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expense And Other Receivables [Text Block]	5. PREPAID EXPENSES AND OTHER RECEIVABLES December 31, March 31, $ $ Prepaid expenses and sundry receivables 52,221 68,484 Prepaid insurance 70,165 136,896 Sales taxes receivable (i) 22,658 22,667 145,044 228,047 (i) Represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

INVENTORIES

INVENTORIES	9 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	INVENTORIES December 31, March 31, $ $ Raw materials 264,334 119,985 Work in progress 14,283 108,264 Finished Goods 23,797 - 302,414 228,249

EQUIPMENT

EQUIPMENT	9 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	7. EQUIPMENT December 31, 2017 March 31, 2017 Accumulated Accumulated Cost Depreciation Net Cost Depreciation Net $ $ $ $ $ $ Computers and electronics 252,120 219,288 32,832 250,538 204,258 46,280 Furniture and fixtures 36,795 27,598 9,197 36,795 26,096 10,699 Demonstration equipment 200,186 92,539 107,647 184,586 44,420 140,166 Manufacturing equipment 88,742 85,509 3,233 88,742 84,982 3,760 Tools and parts 11,422 5,447 5,975 11,422 4,472 6,950 Assets under capital lease 23,019 6,906 16,113 23,019 3,453 19,566 612,284 437,287 174,997 595,102 367,681 227,421 Equipment is recorded at cost less accumulated depreciation. Depreciation expense during the three and nine months period ended December 31, 2017 was $ 21,234 69,606 24,028 57,781

NOTES PAYABLE

NOTES PAYABLE	9 Months Ended
	Dec. 31, 2017
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	NOTES PAYABLE (a) Demand Notes payable The Company repaid on December 31, 2017, all outstanding demand notes payable (“Notes”) except Notes in the aggregate principal amount of $ 50,000 Balance, March 31, 2017 330,600 Accrued interest 7,018 Repayment of principal (208,359) Repayment of interest (79,259) Balance, December 31, 2017 $ 50,000 Interest expense incurred on the Notes totaled $ 2,309 7,018 2,367 3,467 (b) Promissory Notes payable In February 2014, the Company borrowed $ 200,000 10 3,059 12,957 5,041 13,973 Balance, March 31, 2017 236,548 Accrued interest 12,957 Repayment of principal (200,000) Repayment of interest (49,505) Balance, December 31, 2017 $ - (c) Short term Loan In December 2017, a company controlled by a Board member made a short-term loan to the Company of $ 400,000 1.5 2,400 3,200 (d) Convertible Loans Payable In December 2016, several shareholders of the Company agreed to advance the Company $ 1,500,000 500,000 500,000 500,000 2,000,000 17,488 The convertible loans contain the following terms: convertible at the option of the holder at the price of the equity financing or payable on demand upon the completion of an equity financing greater than $5,000,000; automatically convertible at the price of the equity financing upon completion of an equity financing between $3,500,000 and $5,000,000 November 15, 2017 On August 14, 2017, the Company entered into an amendment to these convertible loans, whereby the interest was changed to a fixed rate of 12 3 upon the consummation of an equity or equity-linked round of with an aggregate gross proceeds of $7,000,000, without any action on part of the Holder, the outstanding principal, accrued and unpaid interest and premium amount equal to (25%) of the principal amount less the accrued and unpaid interest, will be converted into shares of new round stock based upon the lesser of (a) the lowest issuance (or conversion) price of new round stock in case there is more than one tranche of new round stock or (b) ($0.25). Further, the Company issued warrants to these debt holders amounting to 20 0.25 An additional $ 2,999,975 4,999,975 381,429 587,699 The Company has recognized a discount against the convertible loans for the relative fair value of the warrants and is accreting the discount using the effective interest rate method. The assumptions used in valuing the warrants using the binomial valuation model 0.25 114 1.91 The Company evaluated the fair value of the warrants attached to the convertible notes as $ 548,178 290,375 Balance, March 31, 2017 2,017,488 Additional principal investment 2,999,975 Fair value of warrants (548,178) Accretion expense 290,375 Accrued Interest 587,699 Balance, December 31, 2017 $ 5,347,359 (e) In May 2017, the Company’s Chinese joint venture partners loaned the Company $500,000 at an interest rate of 8% convertible into the Company’s common shares upon a capital raise (“Qualified Financing”) where gross proceeds exceed $3,000,000 at the lesser of $0.50 and the quotient of the outstanding balance on the conversion date by the price of the Qualified Financing. Additionally, the holders are entitled to warrants equaling 25% of the number of conversion shares to be issued at conversion. 10,082 23,693 Balance, March 31, 2017 - Additional principal investment 500,000 Accrued Interest 23,693 Balance, December 31, 2017 $ 523,693 (f) In December 2017, investors of the Company advanced funds under a new convertible loan offering. These convertible loans bear interest at a fixed rate of 3% per month until the earlie of (a) January 31, 2018 and (b) the consummation of a qualified financing defined as gross proceeds of no less than $7,000,000 and up to $14,000,000 raised in one or more tranches. On the maturity date, without any action on the part of the Holder, the outstanding principal and accrued and unpaid interest under the notes will be converted into shares of new round stock based upon a (15%) discount to the lesser of (i) (A) the VWAP average of the last 30 days ending on the closing of the qualified financing (or, in the event of multiple closings, the lowest VWAP average of the last 30 days ending on each closing of a qualified financing) in the event of a maturity date referred to in clause (b) of the definition thereof, or (B) the VWAP average of the last 30 days before the maturity date in the event of a maturity date referred to in clause (a) of the definition thereof, and (ii) ($0.18). $ 1,200,000 8,800 Balance, March 31, 2017 - Additional principal investment 1,200,000 Accrued Interest 8,800 Balance, December 31, 2017 $ 1,208,800

RELATED PARTY TRANSACTIONS AND

RELATED PARTY TRANSACTIONS AND BALANCES	9 Months Ended
	Dec. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	RELATED PARTY TRANSACTIONS AND BALANCES a) Due from related parties As of December 31, 2017, there was an outstanding loan to the Chief Technology Officer and director of the Company for $ 19,374 18,731 1 649 707 b) Accounts payable and accrued liabilities As at December 31, 2017, $ 89,141 47,307 16,592 97,500 97,500 639,375 4,135 In connection with the acquisition of IMT, the Company acquired a license agreement dated June 8, 2009, pursuant to which the Company pays the licensors an aggregate royalty of 1 As at the effective date of the merger pursuant to the Merger Agreement, a former officer and director received an aggregate of 5,190,376 360,231

SHARE CAPITAL

SHARE CAPITAL	9 Months Ended
	Dec. 31, 2017
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	10. SHARE CAPITAL March 31, 2017 Number of Number of shares $ shares $ Exchangeable Shares: Balance beginning of period/year 47,909,336 47,910 50,000,000 50,000 Converted into common shares (2,000,000) (2,000) (2,090,664) (2,090) Balance at the end of period/year 45,909,336 45,910 47,909,336 47,910 Common Shares Balance at beginning of the period 48,885,107 48,884 22,591,292 22,591 Shares issued on acquisition (Note 3) - - 23,650,000 23,650 Shares issued to exchangeable shares 2,000,000 2,000 2,090,664 2,090 Shares issued for services - - 217,047 217 Options exercised - - 110,096 110 Warrants exercise (a) 5,000,172 5,000 174,759 175 Cashless exercise of warrants - - 51,249 51 Balance at end of the period 55,885,279 55,884 48,885,107 48,884 TOTAL COMMON SHARES 101,794,615 101,794 96,794,443 96,794 (a) During the nine month period ended December 31, 2017, the Company consummated an offer to amend and exercise to its warrant holders, enabling them to exercise their outstanding warrants for $ 0.25 5,000,172 1,125,038 (b) During the nine month period ended December 31, 2016, 51,249 262,045 0.80 43,562 (c) The Company has a commitment to issue 250,000 60,000 70,000 59,500 Special Voting Preferred Share In connection with the Merger (Note 1), on February 26, 2015, the Company entered into a voting and exchange trust agreement (the “Trust Agreement”). Pursuant to the Trust Agreement, the Company issued one share of the Special Voting Preferred Stock, par value $0.001 per share, of the Company (the Special Voting Preferred Share”) to the Trustee, and the parties created a trust for the Trustee to hold the Special Voting Preferred Share for the benefit of the holders of the Exchangeable Shares (the “Beneficiaries”). Pursuant to the Trust Agreement, the Beneficiaries have voting rights in the Company equivalent to what they would have had, had they received shares of common stock in the same amount as the Exchangeable Shares held by the Beneficiaries. In connection with the Merger and the Trust Agreement, effective February 20, 2015, the Company filed a certificate of designation of the Special Voting Preferred Share (the “Special Voting Certificate of Designation”) with the Delaware Secretary of State. Pursuant to the Special Voting Certificate of Designation, one share of the Company’s blank check preferred stock was designated as the Special Voting Preferred Share. The Special Voting Preferred Share entitles the Trustee to exercise the number of votes equal to the number of exchangeable Shares outstanding on a one-for-one basis during the term of the Trust Agreement. The Special Voting Preferred Share is not entitled to receive any dividends or to receive any assets of the Company upon liquidation, and is not convertible into common shares of the Company. The voting rights of the Special Voting Preferred Share will terminate pursuant to and in accordance with the Trust Agreement. The Special Voting Preferred Share will be automatically cancelled at such time as no Exchangeable Shares are held by a Beneficiary.

STOCK OPTIONS

STOCK OPTIONS	9 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	STOCK OPTIONS The purpose of the Company’s equity incentive plan, is to attract, retain and motivate persons of training, experience and leadership to the Company, including their directors, officers and employees, and to advance the interests of the Company by providing such persons with the opportunity, through share options, to acquire an increased proprietary interest in the Company. Options or other securities may be granted in respect of authorized and unissued shares, provided that the aggregate number of shares reserved for issuance upon the exercise of all options or other securities granted under the Plan shall not exceed 15% of the shares of common stock and Exchangeable Shares issued and outstanding (determined as of January 1 of each year). Optioned shares in respect of which options are not exercised shall be available for subsequent options. On November 24, 2015, the Company granted 650,000 694,384 250,000 35,609 106,828 On December 14, 2015, the Company granted 2,495,000 1,260,437 25,000 40,000 351,667 666,667 45,396 450,690 On April 21, 2016, the Company granted 3,000,000 3,895,000 1,000,000 0.25 1,000,000 0.95 1,000,000 1.05 2,582,890 10,169 30,508 On April 26, 2016, the Company granted 250,000 1.00 213,750 17,813 53,438 On August 8, 2016, the Company granted 750,000 1.00 652,068 54,339 163,017 On February 6, 2017, the Company granted 400,000 0.70 245,200 20,433 61,300 On February 13, 2017, the Company granted 250,000 0.68 148,750 12,390 37,188 On August 3, 2017, 1,500,000 0.21 500,000 387,209 22,639 37,370 7 114 1.73 On September 1, 2017, the Company granted 12,215,354 0.161 2,035,892 5 1,832,304 38,173 343,919 10 114 1.91 During the three and nine months ended December 31, 2017, the Company recorded $ 271,001 1,284,257 227,540 592,130 Exercise Price ($) Number of Options Expiry Date Exercisable Options 0.165 264,230 April 1, 2021 264,230 0.23 97,514 June 20, 2021 97,514 0.23 1,981,728 July 1, 2021 1,981,728 0.23 204,471 February 17, 2022 204,471 1.22 400,000 November 24, 2022 266,667 1.00 2,078,333 December 14, 2022 1,803,333 0.95 111,937 March 28, 2023 111,937 1.05 433,027 March 28, 2023 433,027 1.00 250,000 April 26, 2023 83,333 1.00 750,000 August 8, 2023 250,000 0.70 400,000 February 6, 2024 - 0.68 250,000 February 13, 2024 166,667 0.95 31,620 March 3, 2024 31,620 1.05 122,324 March 3, 2024 122,324 0.95 15,810 March 14, 2024 15,810 1.05 61,162 March 14, 2024 61,162 0.95 82,213 September 30, 2024 82,213 1.05 318,042 September 30, 2024 318,042 0.95 7,431 June 2, 2025 7,431 1.05 28,747 June 2, 2025 28,747 0.25 906,077 July 28, 2025 906,077 0.95 671,859 July 29, 2025 671,859 0.25 66,298 December 30, 2025 49,160 0.95 49,160 December 30, 2025 27,261 0.21 2,000,000 August 3, 2024 - 0.161 12,215,354 September 1, 2027 2,035,892 23,797,337 10,025,505 The weighted-average remaining contractual term of the outstanding options was 7.76 5.12 6.23 6.02

WARRANTS

WARRANTS	9 Months Ended
	Dec. 31, 2017
Warrants and Rights Note Disclosure [Abstract]
Shareholders Equity And Share Based Payments Stock Warrant [Text Block]	12. WARRANTS Number of Weighted- Outstanding and exercisable, March 31, 2015 10,823,450 1.35 Issued 7,225,625 1.35 Exercised (148,787) (0.80) Outstanding and exercisable, March 31, 2016 17,900,288 1.35 Exercised (262,045) (0.80) Outstanding and exercisable, March 31, 2017 17,638,243 1.35 Exercised (5,000,172) 0.25 Dilution warrants issued to $0.80 warrant holders 83,752 0.749 Dilution warrants issued to $1.40 warrant holders 941,191 1.2933 Outstanding at December 31, 2017 13,663,014 1.241 During the nine month period ended December 31, 2017, the Company consummated an offer to amend and exercise its then outstanding warrants, enabling the holders of the warrants to exercise such warrants for $ 0.25 1,125,038 83,752 0.80 941,191 1.40 0.749 1.2933 41,025 The Company issued 400,014 June 27, 2020 During the year ended March 31, 2017 a warrant holder exercised 262,045 51,249 During the year ended March 31, 2016, a warrant holder exercised 148,787 45,508 Common share purchase warrants Exercise Number of Expiry Date 1.2933 5,873,289 February 26, 2019 1.2933 1,229,040 March 27, 2019 1.2933 328,166 March 31, 2019 1.2933 2,544,240 April 21, 2019 1.2933 1,201,164 May 27, 2019 1.2933 1,173,370 June 30, 2019 0.7490 1,313,745 February 26, 2019 13,663,014 The weighted-average remaining contractual term of the outstanding warrants was 1.27 1.77 The exercise price and number of underlying shares with respect to the original $0.80 and the $1.40 warrants are expected to be further adjusted pursuant to the anti-dilution provisions therein, as a result of the issuance of the convertible promissory notes and warrants in 2016, 2017 and 2018. The anti-dilution provisions in these warrants are not able to be computed until the convertible promissory notes are converted, and the underlying shares can be determined in accordance with the terms thereunder.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Dec. 31, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	13. COMMITMENTS AND CONTINGENCIES Contingencies From time to time, the Company may be involved in a variety of claims, suits, investigations and proceedings arising in the ordinary course of our business, collections claims, breach of contract claims, labor and employment claims, tax and other matters. Although claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, the Company believes that the resolution of current pending matters will not have a material adverse effect on its business, financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on the Company because of legal costs, diversion of management resources and other factors. Commitments On February 25, 2015, 262,904 241,185 210,323 314,560 320,000

RISK MANAGEMENT

RISK MANAGEMENT	9 Months Ended
	Dec. 31, 2017
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	14. RISK MANAGEMENT The Company’s cash balances are maintained in two banks in Canada and a Canadian Bank subsidiary in the US. US Bank Deposits held in banks in Canada are insured up to $ 100,000 Interest Rate Risk Interest rate risk is the risk that the value of a financial instrument might be adversely affected by a change in the interest rates. The Company has minimal exposure to fluctuations in the market interest rate. In seeking to minimize the risks from interest rate fluctuation the Company manages exposure through its normal operating and financing activities. Liquidity Risk Liquidity risk is the risk that the Company will incur difficulties meeting its financial obligations, as they are due. The Company’s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due. Accounts payable and accrued liabilities are due within the current operating period. The Company has funded its operations through the issuance of capital stock, convertible debt and loans in addition to grants and investment tax credits received from the Government of Canada.

SUBSEQUENT EVENT

SUBSEQUENT EVENT	9 Months Ended
	Dec. 31, 2017
Subsequent Events [Abstract]
Subsequent Events [Text Block]	15. SUBSEQUENT EVENTS (a) Subsequent to December 31, 2017, the Company received an additional $ 606,400 (b) Subsequent to December 31, 2017, the Company issued 3,640,000 0.155 The options will vest over three years - 1/3 on January 24, 2019, 1/3 on January 24, 2020 and 1/3 on January 24, 2021 (c) Subsequent to December 31, 2017, the Company received a short term loan of $ 500,000 1.5

SIGNIFICANT ACCOUNTING POLICI23

SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Unaudited Condensed Consolidated Interim Financial Statements [Policy Text Block]	Unaudited Condensed Consolidated Interim Financial Statements These unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual audited financial statements of the Company and should be read in conjunction with those annual audited financial statements filed on Form 10-K for the year ended March 31, 2017. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period.
Recently Adopted Accounting Pronouncements [Policy Text Block]	Newly Adopted and Recently Issued Accounting Pronouncements In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”. The standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance. The accounting standard is effective for annual reporting periods (including interim reporting periods within those periods) beginning after December 15, 2017. For a public entity, early adoption is not permitted. The impact on the condensed consolidated interim financial statements of adopting ASU 2014-09 will be assessed by management. In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes,” which requires that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015-17 is effective for the fiscal year commencing after December 15, 2017. The Company does not anticipate that the adoption of ASU No. 2015-17 will have a material effect on the condensed consolidated interim financial position or the consolidated results of operations. In January 2016, the FASB issued ASU No. 2016-01 “Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities”. The updates makes several modifications to Subtopic 825-10, including the elimination of the available-for-sale classification of equity investments, and it requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in operations. The update is effective for fiscal years beginning after December 2017. The Company is still assessing the impact that the adoption of ASU 2016-01 will have on the condensed consolidated interim financial position and the consolidated results of operations. In February 2016, the FASB issued ASU 2016-02, “Leases”. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company is still assessing the impact that the adoption of ASU 2016-02 will have on the condensed consolidated interim financial position and the consolidated results of operations. In March 2016, the FASB issued ASU 2016-09, “Compensation – Stock Compensation: Improvements to Employee Share-Based Payment Accounting”. Several aspects of the accounting for share-based payment award transaction are simplified, including (a) income tax consequences; (b) classification of awards as either equity or liabilities; and (c) classification on the statement of cash flows. The amendments are effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods. The Company has adopted this policy during the period and there was no impact on the condensed consolidated interim financial statements. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. This ASU provides eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for the fiscal year commencing after December 15, 2017. The Company is still assessing the impact that the adoption of ASU 2016-15 will have on the condensed consolidated interim statement of cash flows. In January 2017, the FASB issued ASU 2017-01, “Business Combinations: Clarifying the definition of a Business” which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU 2017-01 further states that when substantially all of the fair value of gross assets acquitted is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term “outputs” to be consistent with how it described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after June 30, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date. In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019. In September 2017, the FASB issued ASU 2017-13, “Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842)”. ASU 2017-13 amends the early adoption date option for certain companies related to the adoption of ASU 2014-09 and ASU 2016-02. The Company is not early adopting this standard; however, we are currently assessing the impact that the eventual adoption of this standard will have on the Company.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue from product sales when persuasive evidence of an agreement with customer exists, products are shipped or title passes pursuant to the terms of the agreement, the amount due from the customer is fixed or determinable, collectability is reasonably assured, and there are no significant future performance obligation. Deposits are carried as liabilities until the requirements for revenue recognition are met.
Standard Product Warranty, Policy [Policy Text Block]	Warranty Reserve and Deferred Warranty Revenue The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the balance sheet and amounted to $ 64,957 15,355 30,732
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The functional currency of the Company and its wholly owned subsidiaries is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expand disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs which are as observable as possible and the methods most applicable to the specific situation of each company or valued item. The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, other receivables, accounts payable and accrued liabilities, due from related parties, demand notes payable, promissory notes payable, convertible notes payable, and short-term loans approximate fair value because of the short period of time between the origination of such instruments and their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company’s policy is to recognize transfers into and out of Level 3 as of the date of the event or change in the circumstances that caused the transfer. There were no such transfers during the period.

CHANGE IN ACCOUNTING POLICY (Ta

CHANGE IN ACCOUNTING POLICY (Tables)	9 Months Ended
	Dec. 31, 2017
Disclosure Text Block [Abstract]
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	Income statement Three months period ended December Nine months period ended December As As originally Effect of originally Effect of reported As adjusted change reported As adjusted change Sales $ 372,426 $ 372,426 $ - $ 553,900 $ 553,900 $ - Cost of Sales 334,786 334,786 - 405,680 405,680 - Total operating expenses 1,609,954 1,609,954 - 5,450,290 5,450,290 - Total other expenses (761,896) 9,445 (771,341) (2,897,426) (387,038) 2,510,388 Net income (loss) and comprehensive loss for the period (810,418) (1,581,759) (771,341) (2,404,644) (4,915,032) (2,510,388) Net income (loss) per share (0.01) (0.02) (0.01) (0.03) (0.05) (0.02) Balance sheet As at March 31, 2017 As Effect of reported As adjusted change Current assets $ 1,402,580 $ 1,402,580 $ - Capital assets 227,421 227,421 - Intangible assets 27,338,899 27,338,899 - Total assets 28,968,900 28,968,900 - Warrant derivative liability 959,600 - (959,600) Other current liabilities 4,818,205 4,818,250 45 Total liabilities 5,777,805 4,818,250 (959,555) Common stock 96,794 96,794 - Additional paid in capital 38,640,706 45,088,171 6,447,465 Retained earnings (15,588,554) (21,076,464) (5,487,910) Accumulated other comprehensive income 42,149 42,149 - Total shareholders' equity 23,191,095 24,150,650 959,555 Total liabilities and shareholders' equity 28,968,900 29,968,900 - The change in retained earnings consists of a change in net loss for the year ended March 31 2017, changing from $ 3,936,574 8,069,402 4,132,828 5,487,910 Statement of cash flows As at December 31, 2016 As originally As adjusted Effect of Net loss for the period $ (2,404,644) $ (4,915,032) $ (2,510,388) Adjustment for items not affecting cash Depreciation 57,781 57,781 Interest expense 23,839 23,839 Share-based compensation expense 592,130 592,130 Shares issued for service 59,500 59,500 Change in fair value of warrant derivative liability (2,510,388) - 2,510,388 Change in non-cash working capital items (1,359,164) (1,359,164) Net cash used in operating activities (5,540,946) (5,540,946) - Net cash used in investing activities (9,827) (9,827) - Net cash provided by financing activities 749,968 749,968 - Net decrease in cash and cash equivalents for the period (4,800,805) (4,800,805) - Cash and cash equivalents, beginning of period 5,381,757 5,381,757 - Cash and cash equivalents, end of period 580,952 580,952 -

ACQUISITION (Tables)

ACQUISITION (Tables)	9 Months Ended
	Dec. 31, 2017
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	The following sets forth the purchase price allocation based on management’s best estimates of fair value, including a summary of major classes of consideration transferred and the recognized amounts of assets acquired and liabilities assumed at the acquisition date. As at April 21, 2016 $ Fair value of 23,650,000 shares of common stock (a) 23,177,000 Fair value of vested stock options (b) 2,582,890 Allocation of purchase price: 25,759,890 Cash and cash equivalents 266,635 Accounts receivable 6,490 Inventories 188,879 Prepaid expenses and other current assets 16,839 Equipment 59,749 Liabilities assumed: Accounts payable (241,299) Accrued liabilities (361,029) Customer deposits (86,487) Demand notes payable (324,894) Promissory notes payable (217,808) Bionik advance (c) (1,436,164) Net assets acquired (2,129,089) Patents and exclusive License Agreement 1,306,031 Trademark 2,505,907 Customer relationships 1,431,680 Non compete agreement 61,366 Assembled Workforce 275,720 Goodwill 22,308,275 25,759,890 (a) The fair value of common stock was based on $ 0.98 (b) The fair value of the vested stock options was determined using the Black Scholes option pricing model with the following key assumptions: a risk free rate of 1.59 0 114 (c) Included in the net assets acquired was a loan issued to IMT in the amount of $ 300,000 6 200,000
Business Acquisition, Pro Forma Information [Table Text Block]	The schedule below reflects the intangible assets acquired in the IMT acquisition and the assets amortization period and expense for the three and nine months period ended December 31, 2017 and the year ended March 31, 2017: Amortization Value acquired Expense Value at 3 Months 9 Months Value at Intangible assets acquired period (years) $ $ $ $ $ $ Patents and exclusive License Agreement 9.74 1,306,031 126,375 1,179,656 33,522 100,604 1,079,052 Trademark Indefinite 2,505,907 - 2,505,907 - - 2,505,907 Customer relationships 10 1,431,680 134,931 1,296,749 35,792 107,414 1,189,335 Non compete agreement 2 61,366 28,918 32,448 7,671 23,038 9,410 Assembled Workforce 1 275,720 259,856 15,864 - 15,864 - 5,580,704 550,080 5,030,624 76,985 246,920 4,783,704

PREPAID EXPENSES AND OTHER RE26

PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)	9 Months Ended
	Dec. 31, 2017
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	December 31, March 31, $ $ Prepaid expenses and sundry receivables 52,221 68,484 Prepaid insurance 70,165 136,896 Sales taxes receivable (i) 22,658 22,667 145,044 228,047 (i) Represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

INVENTORIES (Tables)

INVENTORIES (Tables)	9 Months Ended
	Dec. 31, 2017
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	December 31, March 31, $ $ Raw materials 264,334 119,985 Work in progress 14,283 108,264 Finished Goods 23,797 - 302,414 228,249

EQUIPMENT (Tables)

EQUIPMENT (Tables)	9 Months Ended
	Dec. 31, 2017
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Equipment consisted of the following as at December 31, 2017 and March 31, 2017: December 31, 2017 March 31, 2017 Accumulated Accumulated Cost Depreciation Net Cost Depreciation Net $ $ $ $ $ $ Computers and electronics 252,120 219,288 32,832 250,538 204,258 46,280 Furniture and fixtures 36,795 27,598 9,197 36,795 26,096 10,699 Demonstration equipment 200,186 92,539 107,647 184,586 44,420 140,166 Manufacturing equipment 88,742 85,509 3,233 88,742 84,982 3,760 Tools and parts 11,422 5,447 5,975 11,422 4,472 6,950 Assets under capital lease 23,019 6,906 16,113 23,019 3,453 19,566 612,284 437,287 174,997 595,102 367,681 227,421

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	9 Months Ended
	Dec. 31, 2017
Convertible Debt [Table Text Block]	Balance, March 31, 2017 2,017,488 Additional principal investment 2,999,975 Fair value of warrants (548,178) Accretion expense 290,375 Accrued Interest 587,699 Balance, December 31, 2017 $ 5,347,359
Schedule of Short-term Debt [Table Text Block]	Balance, March 31, 2017 - Additional principal investment 500,000 Accrued Interest 23,693 Balance, December 31, 2017 $ 523,693
Convertible Debt [Member]
Schedule of Short-term Debt [Table Text Block]	Balance, March 31, 2017 - Additional principal investment 1,200,000 Accrued Interest 8,800 Balance, December 31, 2017 $ 1,208,800
Demand Notes payable [Member]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Balance, March 31, 2017 330,600 Accrued interest 7,018 Repayment of principal (208,359) Repayment of interest (79,259) Balance, December 31, 2017 $ 50,000
Promissory Note [Member]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Balance, March 31, 2017 236,548 Accrued interest 12,957 Repayment of principal (200,000) Repayment of interest (49,505) Balance, December 31, 2017 $ -

SHARE CAPITAL (Tables)

SHARE CAPITAL (Tables)	9 Months Ended
	Dec. 31, 2017
Stockholders' Equity Note [Abstract]
Schedule of Stockholders Equity [Table Text Block]	March 31, 2017 Number of Number of shares $ shares $ Exchangeable Shares: Balance beginning of period/year 47,909,336 47,910 50,000,000 50,000 Converted into common shares (2,000,000) (2,000) (2,090,664) (2,090) Balance at the end of period/year 45,909,336 45,910 47,909,336 47,910 Common Shares Balance at beginning of the period 48,885,107 48,884 22,591,292 22,591 Shares issued on acquisition (Note 3) - - 23,650,000 23,650 Shares issued to exchangeable shares 2,000,000 2,000 2,090,664 2,090 Shares issued for services - - 217,047 217 Options exercised - - 110,096 110 Warrants exercise (a) 5,000,172 5,000 174,759 175 Cashless exercise of warrants - - 51,249 51 Balance at end of the period 55,885,279 55,884 48,885,107 48,884 TOTAL COMMON SHARES 101,794,615 101,794 96,794,443 96,794 (a) During the nine month period ended December 31, 2017, the Company consummated an offer to amend and exercise to its warrant holders, enabling them to exercise their outstanding warrants for $ 0.25 5,000,172 1,125,038 (b) During the nine month period ended December 31, 2016, 51,249 262,045 0.80 43,562 (c) The Company has a commitment to issue 250,000 60,000 70,000 59,500

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	9 Months Ended
	Dec. 31, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share-based Compensation, Performance Shares Award Outstanding Activity [Table Text Block]	The following is a summary of stock options outstanding and exercisable as of December 31, 2017: Exercise Price ($) Number of Options Expiry Date Exercisable Options 0.165 264,230 April 1, 2021 264,230 0.23 97,514 June 20, 2021 97,514 0.23 1,981,728 July 1, 2021 1,981,728 0.23 204,471 February 17, 2022 204,471 1.22 400,000 November 24, 2022 266,667 1.00 2,078,333 December 14, 2022 1,803,333 0.95 111,937 March 28, 2023 111,937 1.05 433,027 March 28, 2023 433,027 1.00 250,000 April 26, 2023 83,333 1.00 750,000 August 8, 2023 250,000 0.70 400,000 February 6, 2024 - 0.68 250,000 February 13, 2024 166,667 0.95 31,620 March 3, 2024 31,620 1.05 122,324 March 3, 2024 122,324 0.95 15,810 March 14, 2024 15,810 1.05 61,162 March 14, 2024 61,162 0.95 82,213 September 30, 2024 82,213 1.05 318,042 September 30, 2024 318,042 0.95 7,431 June 2, 2025 7,431 1.05 28,747 June 2, 2025 28,747 0.25 906,077 July 28, 2025 906,077 0.95 671,859 July 29, 2025 671,859 0.25 66,298 December 30, 2025 49,160 0.95 49,160 December 30, 2025 27,261 0.21 2,000,000 August 3, 2024 - 0.161 12,215,354 September 1, 2027 2,035,892 23,797,337 10,025,505

WARRANTS (Tables)

WARRANTS (Tables)	9 Months Ended
	Dec. 31, 2017
Warrants and Rights Note Disclosure [Abstract]
Schedule Of Share Based Compensation Stock Purchase Warrants Activity [Table Text Block]	The following is a continuity schedule of the Company’s common share purchase warrants: Number of Weighted- Outstanding and exercisable, March 31, 2015 10,823,450 1.35 Issued 7,225,625 1.35 Exercised (148,787) (0.80) Outstanding and exercisable, March 31, 2016 17,900,288 1.35 Exercised (262,045) (0.80) Outstanding and exercisable, March 31, 2017 17,638,243 1.35 Exercised (5,000,172) 0.25 Dilution warrants issued to $0.80 warrant holders 83,752 0.749 Dilution warrants issued to $1.40 warrant holders 941,191 1.2933 Outstanding at December 31, 2017 13,663,014 1.241
Schedule of Common Share Purchase Warrants Outstanding [Table Text Block]	The following is a summary of common share purchase warrants outstanding after the warrant offer to amend and exercise the additional warrant issue and the re-pricing of the warrants as of December 31, 2017: Exercise Number of Expiry Date 1.2933 5,873,289 February 26, 2019 1.2933 1,229,040 March 27, 2019 1.2933 328,166 March 31, 2019 1.2933 2,544,240 April 21, 2019 1.2933 1,201,164 May 27, 2019 1.2933 1,173,370 June 30, 2019 0.7490 1,313,745 February 26, 2019 13,663,014

NATURE OF OPERATIONS (Details T

NATURE OF OPERATIONS (Details Textual)	1 Months Ended		3 Months Ended		9 Months Ended
	Apr. 21, 2016shares	Feb. 26, 2015shares	Dec. 31, 2017USD ($)shares	Dec. 31, 2016USD ($)	Dec. 31, 2017USD ($)shares	Dec. 31, 2016USD ($)	Mar. 31, 2017USD ($)shares	Dec. 31, 2014shares
Working Capital Surplus (Deficit) | $			$ 8,535,488		$ 8,535,488		$ 3,415,670
Net income (loss) and comprehensive loss for the period | $			$ (2,580,759)	$ (1,581,759)	$ (8,436,636)	$ (4,915,032)
Stockholders' Equity, Reverse Stock Split					1-for-0.831105
Common Stock, Shares Authorized | shares			250,000,000		250,000,000		150,000,000	200,000,000
Retained Earnings (Accumulated Deficit) | $			$ (29,554,125)		$ (29,554,125)		$ (21,076,464)
Interactive Motion Technologies, Inc. [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | shares	23,650,000
Share Exchange Agreement [Member]
Stock Issued During Period, Shares, New Issues | shares		50,000,000
Debt Instrument, Convertible, Conversion Ratio		3.14
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage		100.00%

CHANGE IN ACCOUNTING POLICY (De

CHANGE IN ACCOUNTING POLICY (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Sales	$ 260,960	$ 372,426	$ 570,327	$ 553,900
Cost of Sales	88,357	334,786	177,482	405,680
Total operating expenses	2,347,916	1,609,954	8,068,811	5,450,290
Total other expenses	405,446	9,445	760,670	(387,038)
Net income (loss) and comprehensive loss for the period	$ (2,580,759)	$ (1,581,759)	$ (8,436,636)	$ (4,915,032)
Net income (loss) per share		$ (0.02)		$ (0.05)
Scenario, Previously Reported [Member]
Sales		$ 372,426		$ 553,900
Cost of Sales		334,786		405,680
Total operating expenses		1,609,954		5,450,290
Total other expenses		(761,896)		(2,897,426)
Net income (loss) and comprehensive loss for the period		$ (810,418)		$ (2,404,644)
Net income (loss) per share		$ (0.01)		$ (0.03)
Scenario, Adjustment [Member]
Sales		$ 0		$ 0
Cost of Sales		0		0
Total operating expenses		0		0
Total other expenses		(771,341)		2,510,388
Net income (loss) and comprehensive loss for the period		$ (771,341)		$ (2,510,388)
Net income (loss) per share		$ (0.01)		$ (0.02)

CHANGE IN ACCOUNTING POLICY (35

CHANGE IN ACCOUNTING POLICY (Details 1) - USD ($)	Dec. 31, 2017	Mar. 31, 2017	Mar. 31, 2016
Current assets	$ 1,772,065	$ 1,402,580
Capital assets	174,997	227,421
Intangible assets	4,783,704	5,030,624
Total assets	29,039,041	28,968,900
Warrant derivative liability		0
Other current liabilities	10,307,553	4,818,250
Total liabilities		4,818,250
Common stock	101,794	96,794
Additional paid in capital	48,081,670	45,088,171
Retained earnings	(29,554,125)	(21,076,464)
Accumulated other comprehensive income	42,149	42,149
Total shareholders' equity	18,731,488	24,150,650	$ 5,399,851
Total liabilities and shareholders' equity	$ 29,039,041	28,968,900
Scenario, Previously Reported [Member]
Current assets		1,402,580
Capital assets		227,421
Intangible assets		27,338,899
Total assets		28,968,900
Warrant derivative liability		959,600
Other current liabilities		4,818,205
Total liabilities		5,777,805
Common stock		96,794
Additional paid in capital		38,640,706
Retained earnings		(15,588,554)
Accumulated other comprehensive income		42,149
Total shareholders' equity		23,191,095
Total liabilities and shareholders' equity		28,968,900
Scenario, Adjustment [Member]
Current assets		0
Capital assets		0
Intangible assets		0
Total assets		0
Warrant derivative liability		(959,600)
Other current liabilities		45
Total liabilities		(959,555)
Common stock		0
Additional paid in capital		6,447,465
Retained earnings		(5,487,910)	$ 5,487,910
Accumulated other comprehensive income		0
Total shareholders' equity		959,555
Total liabilities and shareholders' equity		$ 0

CHANGE IN ACCOUNTING POLICY (36

CHANGE IN ACCOUNTING POLICY (Details 2) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2016
Net loss for the period	$ (2,580,759)	$ (1,581,759)	$ (8,436,636)	$ (4,915,032)
Depreciation	21,234	24,028	69,606	57,781
Interest Expense			640,168	23,839
Share-based compensation expense	271,001	227,540	1,284,257	592,130
Shares issued for service			60,000	59,500
Change in fair value of warrant derivative liability				0
Change in non-cash working capital items				(1,359,164)
Net cash used in operating activities				(5,540,946)
Net cash used in investing activities				(9,827)
Net cash provided by financing activities				749,968
Net decrease in cash and cash equivalents for the period			455,011	(4,800,805)
Cash and cash equivalents, beginning of period		580,952	543,650	5,381,757
Cash and cash equivalents, end of period	$ 998,661	580,952	$ 543,650	5,381,757	$ 580,952
Scenario, Previously Reported [Member]
Net loss for the period		(810,418)		(2,404,644)
Depreciation				57,781
Interest Expense				23,839
Share-based compensation expense				592,130
Shares issued for service				59,500
Change in fair value of warrant derivative liability				(2,510,388)
Change in non-cash working capital items				(1,359,164)
Net cash used in operating activities				(5,540,946)
Net cash used in investing activities				(9,827)
Net cash provided by financing activities				749,968
Net decrease in cash and cash equivalents for the period				(4,800,805)
Cash and cash equivalents, beginning of period		580,952		5,381,757
Cash and cash equivalents, end of period		580,952		5,381,757
Scenario, Adjustment [Member]
Net loss for the period		(771,341)		(2,510,388)
Depreciation
Interest Expense
Share-based compensation expense
Shares issued for service
Change in fair value of warrant derivative liability				2,510,388
Change in non-cash working capital items				0
Net cash used in operating activities				0
Net cash used in investing activities				0
Net cash provided by financing activities				0
Net decrease in cash and cash equivalents for the period				0
Cash and cash equivalents, beginning of period		0		0
Cash and cash equivalents, end of period		$ 0		$ 0

CHANGE IN ACCOUNTING POLICY (37

CHANGE IN ACCOUNTING POLICY (Details Textuals) - USD ($)	9 Months Ended		12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Retained Earnings (Accumulated Deficit)	$ (29,554,125)		$ (21,076,464)
Net (loss) income for the period	(8,436,636)	$ (4,915,032)	(8,069,402)
Scenario, Previously Reported [Member]
Retained Earnings (Accumulated Deficit)			(15,588,554)
Scenario, Adjustment [Member]
Retained Earnings (Accumulated Deficit)			(5,487,910)	$ 5,487,910
Retained Earnings [Member]
Net (loss) income for the period	$ (8,436,636)		(8,069,402)
Retained Earnings [Member] | Scenario, Previously Reported [Member]
Net (loss) income for the period			3,936,574
Retained Earnings [Member] | Scenario, Adjustment [Member]
Net (loss) income for the period			$ 4,132,828

SIGNIFICANT ACCOUNTING POLICI38

SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($)	3 Months Ended	9 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2017
Significant Accounting Policies [Line Items]
Standard and Extended Product Warranty Accrual	$ 64,957		$ 64,957
Product Warranty Expense	$ 15,355	$ 30,732

ACQUISITION (Details)

ACQUISITION (Details) - USD ($)		1 Months Ended
		Apr. 21, 2016	Dec. 31, 2017	Mar. 31, 2017
Business Acquisition [Line Items]
Fair value of 23,650,000 shares of common stock	[1]	$ 23,177,000
Fair value of vested stock options	[2]	2,582,890
Total Consideration Paid		25,759,890
Allocation of purchase price:
Cash and cash equivalents		266,635
Accounts receivable		6,490
Inventories		188,879
Prepaid expenses and other current assets		16,839
Equipment		59,749
Liabilities assumed:
Accounts payable		(241,299)
Accrued liabilities		(361,029)
Customer deposits		(86,487)
Demand notes payable		(324,894)
Promissory notes payable		(217,808)
Bionik advance	[3]	(1,436,164)
Net assets acquired		(2,129,089)
Goodwill		22,308,275	$ 22,308,275	$ 22,308,275
Total Allocation of purchase price		25,759,890
Patents and exclusive License Agreement [Member]
Liabilities assumed:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		1,306,031
Customer Relationships [Member]
Liabilities assumed:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		1,431,680
Non compete agreement [Member]
Liabilities assumed:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		61,366
Assembled Workforce [Member]
Liabilities assumed:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		275,720
Trademarks [Member]
Liabilities assumed:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		$ 2,505,907
[1]	The fair value of common stock was based on $0.98, which was the closing market price of the Company’s common stock on April 21, 2016.
[2]	The fair value of the vested stock options was determined using the Black Scholes option pricing model with the following key assumptions: a risk free rate of 1.59%, dividend and forfeiture rates of 0% and expected volatility of 114% which is consistent with the Company’s assumptions (Note 11).
[3]	Included in the net assets acquired was a loan issued to IMT in the amount of $300,000 under normal commercial terms. The loan carried an interest rate of 6% and were secured by all the assets of IMT subject to a $200,000 subordination to a third party financial services company, which was released in April 2016.

ACQUISITION (Details 1)

ACQUISITION (Details 1) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Apr. 21, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2017
Business Acquisition [Line Items]
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 5,580,704
Amortization of Intangible Assets		$ 76,985	$ 0	$ 246,920	$ 0	$ 550,080
Intangible Assets, Net (Excluding Goodwill)		4,783,704		4,783,704		$ 5,030,624
Patents and exclusive License Agreement [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life						9 years 8 months 26 days
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	1,306,031
Amortization of Intangible Assets		33,522		100,604		$ 126,375
Intangible Assets, Net (Excluding Goodwill)		1,079,052		1,079,052		$ 1,179,656
Trademark [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life						Indefinite
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	2,505,907
Amortization of Intangible Assets		0		0		$ 0
Intangible Assets, Net (Excluding Goodwill)		2,505,907		2,505,907		$ 2,505,907
Customer relationships [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life						10 years
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	1,431,680
Amortization of Intangible Assets		35,792		107,414		$ 134,931
Intangible Assets, Net (Excluding Goodwill)		1,189,335		1,189,335		$ 1,296,749
Non compete agreement [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life						2 years
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	61,366
Amortization of Intangible Assets		7,671		23,038		$ 28,918
Intangible Assets, Net (Excluding Goodwill)		9,410		9,410		$ 32,448
Assembled Workforce [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life						1 year
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 275,720
Amortization of Intangible Assets		0		15,864		$ 259,856
Intangible Assets, Net (Excluding Goodwill)		$ 0		$ 0		$ 15,864

ACQUISITION (Details Textual)

ACQUISITION (Details Textual) - USD ($)	1 Months Ended
	Apr. 21, 2016	Dec. 31, 2017
Business Acquisition [Line Items]
Fair Value Assumptions, Risk Free Interest Rate	1.59%
Fair Value Assumption Forfeited rate	0.00%
Fair Value Assumptions, Expected Volatility Rate	114.00%
Debt Instrument, Interest Rate, Stated Percentage		1.50%
Exercise Price 0.25 [Member]
Business Acquisition [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.25
Exercise Price 0.95 [Member]
Business Acquisition [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 0.95
Exercise Price 1.05 [Member]
Business Acquisition [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 1.05
Interactive Motion Technologies, Inc. [Member]
Business Acquisition [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	100.00%
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	23,650,000
Business Acquisition, Number Of Option Acquired	3,895,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	3,000,000
Allocated Share-based Compensation Expense	$ 2,582,890
Share Price	$ 0.98
Stock Issued During Period, Shares, Acquisitions	300,000
Debt Instrument, Interest Rate, Stated Percentage	6.00%
Subordinated Debt	$ 200,000

PREPAID EXPENSES AND OTHER RE42

PREPAID EXPENSES AND OTHER RECEIVABLES (Details) - USD ($)		Dec. 31, 2017	Mar. 31, 2017
Prepaid Expense And Other Receivables [Line Items]
Prepaid expenses and sundry receivables		$ 52,221	$ 68,484
Prepaid insurance		70,165	136,896
Sales taxes receivable	[1]	22,658	22,667
Prepaid Expense and Other Assets		$ 145,044	$ 228,047
[1]	Represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

INVENTORIES (Details)

INVENTORIES (Details) - USD ($)	Dec. 31, 2017	Mar. 31, 2017
Inventory [Line Items]
Raw Materials	$ 264,334	$ 119,985
Work in Progress	14,283	108,264
Finished Goods	23,797	0
Inventory, Net	$ 302,414	$ 228,249

EQUIPMENT (Details)

EQUIPMENT (Details) - USD ($)	Dec. 31, 2017	Mar. 31, 2017
Property, Plant and Equipment [Line Items]
Equipment, Cost	$ 612,284	$ 595,102
Accumulated Depreciation	437,287	367,681
Equipment, Net	174,997	227,421
Computers and electronics [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	252,120	250,538
Accumulated Depreciation	219,288	204,258
Equipment, Net	32,832	46,280
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	36,795	36,795
Accumulated Depreciation	27,598	26,096
Equipment, Net	9,197	10,699
Demonstration equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	200,186	184,586
Accumulated Depreciation	92,539	44,420
Equipment, Net	107,647	140,166
Manufacturing equipment [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	88,742	88,742
Accumulated Depreciation	85,509	84,982
Equipment, Net	3,233	3,760
Tools and parts [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	11,422	11,422
Accumulated Depreciation	5,447	4,472
Equipment, Net	5,975	6,950
Assets under capital lease [Member]
Property, Plant and Equipment [Line Items]
Equipment, Cost	23,019	23,019
Accumulated Depreciation	6,906	3,453
Equipment, Net	$ 16,113	$ 19,566

EQUIPMENT (Details Textual)

EQUIPMENT (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment [Line Items]
Depreciation	$ 21,234	$ 24,028	$ 69,606	$ 57,781

NOTES PAYABLE (Details)

NOTES PAYABLE (Details) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Repayment of principal			$ (208,359)	$ 0
Repayment of interest			(79,259)	0
IMT Notes [Member]
Balance, March 31, 2017			330,600
Accrued interest	$ 2,309	$ 2,367	7,018	$ 3,467
Repayment of principal			(208,359)
Repayment of interest			(79,259)
Balance, December 31, 2017	$ 50,000		$ 50,000

NOTES PAYABLE (Details 1)

NOTES PAYABLE (Details 1) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Balance, March 31, 2017			$ 236,548
Balance, December 31, 2017	$ 0		0
Promissory Note [Member]
Balance, March 31, 2017			236,548
Accrued interest	3,059	$ 5,041	12,957	$ 13,973
Repayment of principal			(200,000)
Repayment of interest			(49,505)
Balance, December 31, 2017	$ 0		$ 0

NOTES PAYABLE (Details 2)

NOTES PAYABLE (Details 2) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Balance, March 31, 2017			$ 236,548
Fair value of warrants				$ 0
Accretion expense	$ 216,302	$ 0	290,375	$ 0
Balance, December 31, 2017	0		0
Convertible Debt [Member]
Balance, March 31, 2017			2,017,488
Additional principal investment			2,999,975
Fair value of warrants			(548,178)
Accretion expense			290,375
Accrued Interest	381,429		587,699
Balance, December 31, 2017	$ 5,347,359		$ 5,347,359

NOTES PAYABLE (Details 3)

NOTES PAYABLE (Details 3) - USD ($)	3 Months Ended	9 Months Ended
	Dec. 31, 2017	Dec. 31, 2017
Balance, March 31, 2017		$ 236,548
Balance, December 31, 2017	$ 0	0
Convertible Debt [Member]
Balance, March 31, 2017		2,017,488
Additional principal investment		2,999,975
Accrued Interest	381,429	587,699
Balance, December 31, 2017	$ 5,347,359	$ 5,347,359

NOTES PAYABLE (Details 4)

NOTES PAYABLE (Details 4) - USD ($)	3 Months Ended	9 Months Ended
	Dec. 31, 2017	Dec. 31, 2017
Balance, March 31, 2017		$ 236,548
Balance, December 31, 2017	$ 0	0
Convertible Debt One [Member]
Balance, March 31, 2017		0
Additional principal investment		1,200,000
Accrued Interest	8,800	8,800
Balance, December 31, 2017	$ 1,208,800	$ 1,208,800

NOTES PAYABLE (Details Textual)

NOTES PAYABLE (Details Textual) - USD ($)	Aug. 14, 2017	Jan. 31, 2018	Dec. 31, 2016	Apr. 21, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2017	Jan. 15, 2017	Feb. 28, 2014
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage					1.50%		1.50%
Due to Officers or Stockholders					$ 4,999,975		$ 4,999,975
Fair Value Assumptions, Expected Volatility Rate				114.00%
Fair Value Assumptions, Risk Free Interest Rate				1.59%
Warrants Not Settleable in Cash, Fair Value Disclosure					548,178		548,178
Accretion Expense					216,302	$ 0	290,375	$ 0
Short-term Debt					50,000		50,000		$ 330,600
Proceeds from Related Party Debt							400,000	0
Interest Expense, Related Party					$ 2,400	0	2,400	0
Proceeds from Convertible Debt							$ 4,699,975	483,333
Warrant [Member]
Debt Instrument [Line Items]
Fair Value Assumptions, Exercise Price					$ 0.25		$ 0.25
Fair Value Assumptions, Expected Volatility Rate							114.00%
Fair Value Assumptions, Risk Free Interest Rate							1.91%
Fair Value Assumptions, Expected Term							5 years
Fair Value Measurements, Valuation Techniques							binomial valuation model
Convertible Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	12.00%
Interest Expense, Debt					$ 381,429		$ 587,699
Debt Instrument, Face Amount			$ 1,500,000			1,500,000		1,500,000	2,000,000
Debt Instrument, Maturity Date							Nov. 15, 2017
Debt Instrument, Convertible, Terms of Conversion Feature	upon the consummation of an equity or equity-linked round of with an aggregate gross proceeds of $7,000,000, without any action on part of the Holder, the outstanding principal, accrued and unpaid interest and premium amount equal to (25%) of the principal amount less the accrued and unpaid interest, will be converted into shares of new round stock based upon the lesser of (a) the lowest issuance (or conversion) price of new round stock in case there is more than one tranche of new round stock or (b) ($0.25).		The convertible loans contain the following terms: convertible at the option of the holder at the price of the equity financing or payable on demand upon the completion of an equity financing greater than $5,000,000; automatically convertible at the price of the equity financing upon completion of an equity financing between $3,500,000 and $5,000,000				On the maturity date, without any action on the part of the Holder, the outstanding principal and accrued and unpaid interest under the notes will be converted into shares of new round stock based upon a (15%) discount to the lesser of (i) (A) the VWAP average of the last 30 days ending on the closing of the qualified financing (or, in the event of multiple closings, the lowest VWAP average of the last 30 days ending on each closing of a qualified financing) in the event of a maturity date referred to in clause (b) of the definition thereof, or (B) the VWAP average of the last 30 days before the maturity date in the event of a maturity date referred to in clause (a) of the definition thereof, and (ii) ($0.18).
Debt Instrument Monthly Interest Rate	3.00%
Debt Instrument Principal Percentage	20.00%
Debt Instrument, Convertible, Conversion Price	$ 0.25
Proceeds from Contributions from Affiliates							$ 2,999,975
Accretion Expense							$ 290,375
Debt Instrument, Interest Rate Terms							These convertible loans bear interest at a fixed rate of 3% per month until the earlie of (a) January 31, 2018 and (b) the consummation of a qualified financing defined as gross proceeds of no less than $7,000,000 and up to $14,000,000 raised in one or more tranches.
Proceeds from Convertible Debt							$ 1,200,000
Convertible Loans Payable [Member]
Debt Instrument [Line Items]
Interest Payable, Current									17,488
Convertible Debt One [Member]
Debt Instrument [Line Items]
Interest Expense, Debt					8,800		8,800
Proceeds from Contributions from Affiliates							1,200,000
First Tranches [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount			$ 500,000			500,000		500,000
Second Tranches [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount										$ 500,000
Third Tranches [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount									500,000
Subsequent Event [Member]
Debt Instrument [Line Items]
Repayments of Related Party Debt		$ 3,200
IMT Notes [Member]
Debt Instrument [Line Items]
Notes Payable					50,000		50,000		$ 330,600
Interest Expense, Debt					2,309	2,367	7,018	3,467
Promissory Note [Member]
Debt Instrument [Line Items]
Notes Payable											$ 200,000
Debt Instrument, Interest Rate, Stated Percentage											10.00%
Interest Expense, Debt					3,059	$ 5,041	12,957	$ 13,973
Joint Venture Partner [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Interest Expense, Debt					$ 10,082		$ 23,693
Debt Instrument, Convertible, Terms of Conversion Feature							the Companys Chinese joint venture partners loaned the Company $500,000 at an interest rate of 8% convertible into the Companys common shares upon a capital raise (Qualified Financing) where gross proceeds exceed $3,000,000 at the lesser of $0.50 and the quotient of the outstanding balance on the conversion date by the price of the Qualified Financing. Additionally, the holders are entitled to warrants equaling 25% of the number of conversion shares to be issued at conversion.

RELATED PARTY TRANSACTIONS AN52

RELATED PARTY TRANSACTIONS AND BALANCES (Details Textual) - USD ($)	9 Months Ended	12 Months Ended
	Dec. 31, 2017	Mar. 31, 2017
Related Party Transaction [Line Items]
Accrued interest receivable	$ 649	$ 707
Royalty on Sales, Percentage	1.00%
Related Party Transaction, Rate	1.00%
Accounts Payable, Current	$ 794,875	784,771
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	89,141	0
Accounts Payable, Current		10,169
Chief Technology Officer [Member]
Related Party Transaction [Line Items]
Due from Related Parties	19,374	18,731
Accounts Payable, Related Parties	47,307	0
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	16,592	0
Chief Commercial Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	$ 97,500	97,500
Interactive Motion Technologies, Inc. [Member] | Director [Member]
Related Party Transaction [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	5,190,376
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	360,231
Board of Directors Chairman [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	$ 639,375	$ 4,135

SHARE CAPITAL (Details)

SHARE CAPITAL (Details) - USD ($)		9 Months Ended	12 Months Ended
		Dec. 31, 2017	Mar. 31, 2017
Opening Balance		$ 24,150,650	$ 5,399,851
Shares issued on acquisition (Note 3)			23,177,000
Options exercised			18,166
Warrants exercised		1,125,038	40,195
Cashless exercise of warrants (iv)			0
Closing Balance		$ 18,731,488	$ 24,150,650
Exchangable Shares [Member]
Opening Balance (in shares)		47,909,336	50,000,000
Opening Balance		$ 47,910	$ 50,000
Converted into common shares (in shares)		(2,000,000)	(2,090,664)
Converted into common shares		$ (2,000)	$ (2,090)
Closing Balance (in shares)		45,909,336	47,909,336
Closing Balance		$ 45,910	$ 47,910
Common Shares [Member]
Opening Balance (in shares)		48,885,107	22,591,292
Opening Balance		$ 48,884	$ 22,591
Shares issued on acquisition (Note 3)		$ 0	$ 23,650
Shares issued on acquisition (Note 3) (in shares)		0	23,650,000
Shares issued to exchangeable shareholders (in shares)		2,000,000	2,090,664
Shares issued to exchangeable shareholders		$ 2,000	$ 2,090
Shares issued for services (in shares)		0	217,047
Shares issued for services		$ 0	$ 217
Options exercised (in shares)		0	110,096
Options exercised		$ 0	$ 110
Warrants exercised	[1]	$ 5,000	$ 175
Warrants exercised (in shares)	[1]	5,000,172	174,759
Cashless exercise of warrants (iv) (in shares)		0	51,249
Cashless exercise of warrants (iv)		$ 0	$ 51
Closing Balance (in shares)		55,885,279	48,885,107
Closing Balance		$ 55,884	$ 48,884
Common Shares And Exchangeable Shares [Member]
Opening Balance (in shares)		96,794,443
Opening Balance		$ 96,794
Closing Balance (in shares)		101,794,615	96,794,443
Closing Balance		$ 101,794	$ 96,794
[1]	During the nine month period ended December 31, 2017, the Company consummated an offer to amend and exercise to its warrant holders, enabling them to exercise their outstanding warrants for $0.25 per share, and as a result, 5,000,172 common shares were issued for net proceeds of $1,125,038 (Note 12).

SHARE CAPITAL (Details Textual)

SHARE CAPITAL (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation	$ 271,001	$ 227,540	$ 1,284,257	$ 651,630
Proceeds from Warrant Exercises			$ 1,125,038	$ 0
Number of Shares Committed to Issue			250,000
Common Shares [Member]
Stock Issued During Period, Shares, Issued for Services				70,000
Stock Issued During Period, Value, Issued for Services				$ 59,500
Share-based Compensation			$ 60,000	$ 43,562
Investor Relation And Consultine Services [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.80		$ 0.80
Stock Issued During Period, Shares, Upon Cashless Exercise Of Warrants				51,249
Number Of Warrants Exercised				262,045
Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.25		$ 0.25
Stock Issued During Period, Shares, Warrants Exercised			5,000,172
Proceeds from Warrant Exercises			$ 1,125,038

STOCK OPTIONS (Details)

STOCK OPTIONS (Details) - Employee Stock Option [Member]	9 Months Ended
	Dec. 31, 2017$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options	23,797,337
Number of Exercisable Options	10,025,505
Stock Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.165
Number of Options	264,230
Expiry Date	Apr. 1, 2021
Number of Exercisable Options	264,230
Stock Option Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.23
Number of Options	97,514
Expiry Date	Jun. 20, 2021
Number of Exercisable Options	97,514
Stock Option Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.23
Number of Options	1,981,728
Expiry Date	Jul. 1, 2021
Number of Exercisable Options	1,981,728
Stock Option Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.23
Number of Options	204,471
Expiry Date	Feb. 17, 2022
Number of Exercisable Options	204,471
Stock Option Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1.22
Number of Options	400,000
Expiry Date	Nov. 24, 2022
Number of Exercisable Options	266,667
Stock Option Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1
Number of Options	2,078,333
Expiry Date	Dec. 14, 2022
Number of Exercisable Options	1,803,333
Stock Option Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.95
Number of Options	111,937
Expiry Date	Mar. 28, 2023
Number of Exercisable Options	111,937
Stock Option Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1.05
Number of Options	433,027
Expiry Date	Mar. 28, 2023
Number of Exercisable Options	433,027
Stock Option Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1
Number of Options	250,000
Expiry Date	Apr. 26, 2023
Number of Exercisable Options	83,333
Stock Option Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1
Number of Options	750,000
Expiry Date	Aug. 8, 2023
Number of Exercisable Options	250,000
Stock Option Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.70
Number of Options	400,000
Expiry Date	Feb. 6, 2024
Number of Exercisable Options	0
Stock Option Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.68
Number of Options	250,000
Expiry Date	Feb. 13, 2024
Number of Exercisable Options	166,667
Stock Option Thirteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.95
Number of Options	31,620
Expiry Date	Mar. 3, 2024
Number of Exercisable Options	31,620
Stock Option Fourteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1.05
Number of Options	122,324
Expiry Date	Mar. 3, 2024
Number of Exercisable Options	122,324
Stock Option Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.95
Number of Options	15,810
Expiry Date	Mar. 14, 2024
Number of Exercisable Options	15,810
Stock Option Sixteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1.05
Number of Options	61,162
Expiry Date	Mar. 14, 2024
Number of Exercisable Options	61,162
Stock Option Seventeen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.95
Number of Options	82,213
Expiry Date	Sep. 30, 2024
Number of Exercisable Options	82,213
Stock Option Eighteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1.05
Number of Options	318,042
Expiry Date	Sep. 30, 2024
Number of Exercisable Options	318,042
Stock Option Nineteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.95
Number of Options	7,431
Expiry Date	Jun. 2, 2025
Number of Exercisable Options	7,431
Stock Option Twenty [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 1.05
Number of Options	28,747
Expiry Date	Jun. 2, 2025
Number of Exercisable Options	28,747
Stock Option Twenty One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.25
Number of Options	906,077
Expiry Date	Jul. 28, 2025
Number of Exercisable Options	906,077
Stock Option Twenty Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.95
Number of Options	671,859
Expiry Date	Jul. 29, 2025
Number of Exercisable Options	671,859
Stock Option Twenty Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.25
Number of Options	66,298
Expiry Date	Dec. 30, 2025
Number of Exercisable Options	49,160
Stock Option Twenty Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.95
Number of Options	49,160
Expiry Date	Dec. 30, 2025
Number of Exercisable Options	27,261
Stock Option Twenty Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.21
Number of Options	2,000,000
Expiry Date	Aug. 3, 2024
Number of Exercisable Options	0
Stock Option Twenty Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price | $ / shares	$ 0.161
Number of Options	12,215,354
Expiry Date	Sep. 1, 2027
Number of Exercisable Options	2,035,892

STOCK OPTIONS (Details Textual)

STOCK OPTIONS (Details Textual) - USD ($)

Sep. 01, 2017

Aug. 03, 2017

Feb. 06, 2017

Aug. 08, 2016

Dec. 14, 2015

Feb. 13, 2017

Apr. 26, 2016

Apr. 21, 2016

Nov. 24, 2015

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2017

Dec. 31, 2016

Mar. 31, 2017

Mar. 31, 2016

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term

5 years 1 month 13 days

7 years 9 months 4 days

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term

6 years 7 days

6 years 2 months 23 days

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term

10 years

7 years

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

114.00%

114.00%

Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate

1.91%

1.73%

Stock or Unit Option Plan Expense

$ 271,001

$ 227,540

$ 1,284,257

$ 592,130

Business Combination, Consideration Transferred, Other

[1]

$ 2,582,890

Stock Option One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 351,667

Director and Employees and Consultant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

40,000

25,000

Allocated Share-based Compensation Expense

45,396

450,690

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

666,667 options that were to vest equally December 14, 2017 and 2018 immediately vested.

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

666,667

Employees of Bionik Inc [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 1

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

3,895,000

Allocated Share-based Compensation Expense

17,813

53,438

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

750,000

250,000

3,000,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value

$ 1

Allocated Share-based Compensation Expense, Net of Tax

54,339

163,017

Business Combination, Consideration Transferred, Other

$ 652,068

$ 213,750

$ 2,582,890

Employees of Bionik Inc [Member] | Exercise Price Range One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.25

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

1,000,000

Employees of Bionik Inc [Member] | Exercise Price Range Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.95

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

1,000,000

Employees of Bionik Inc [Member] | Exercise Price Range Three [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 1.05

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

1,000,000

Employees of Bionik Inc [Member] | Unvested option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Allocated Share-based Compensation Expense

10,169

30,508

Employees [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

650,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

250,000

Allocated Share-based Compensation Expense

35,609

$ 106,828

Fair Value Of Options

$ 694,384

Director and Employees and Consultant One [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

2,495,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

351,667

Fair Value Of Options

$ 1,260,437

Employee Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.70

Allocated Share-based Compensation Expense

20,433

$ 61,300

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

400,000

Business Combination, Consideration Transferred, Other

$ 245,200

Consultant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.68

Allocated Share-based Compensation Expense

12,390

37,188

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

250,000

Business Combination, Consideration Transferred, Other

$ 148,750

Executive Employee [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

1,500,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.21

Allocated Share-based Compensation Expense

22,639

37,370

Fair Value Of Options

387,209

Share Based Compensation Arrangement By Share Based Payment Award Additional Options Grants In Period Gross

500,000

Executive Employee and Consultant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

12,215,354

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price

$ 0.161

Fair Value Of Options

1,832,304

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

5 years

Allocated Share-based Compensation Expense, Net of Tax

$ 38,173

$ 343,919

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights

50% of the remaining options vest on performance being met and 50% vest annually over 5 years.

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares

2,035,892

[1]

The fair value of the vested stock options was determined using the Black Scholes option pricing model with the following key assumptions: a risk free rate of 1.59%, dividend and forfeiture rates of 0% and expected volatility of 114% which is consistent with the Company’s assumptions (Note 11).

WARRANTS (Details)

WARRANTS (Details) - $ / shares	9 Months Ended	12 Months Ended
	Dec. 31, 2017	Mar. 31, 2017	Mar. 31, 2016
Number of Warrants, Outstanding and exercisable, Beginning balance	17,638,243	17,900,288	10,823,450
Number of Warrants, Issued			7,225,625
Number of Warrants, Issued, Exercised	(5,000,172)	(262,045)	(148,787)
Number of Warrants, Outstanding and exercisable, Ending balance	13,663,014	17,638,243	17,900,288
Weighted-Average Exercise Price, Outstanding and exercisable, Beginning balance	$ 1.35	$ 1.35	$ 1.35
Weighted-Average Exercise Price, Issued			1.35
Weighted-Average Exercise Price, Exercised	0.25	(0.80)	(0.80)
Weighted-Average Exercise Price, Outstanding and exercisable, Ending balance	$ 1.241	$ 1.35	$ 1.35
Additional Warrants Issued One
Number of Warrants, Issued	83,752
Weighted-Average Exercise Price, Issued	$ 0.749
Additonal Warrant Issued Two
Number of Warrants, Issued	941,191
Weighted-Average Exercise Price, Issued	$ 1.2933

WARRANTS (Details 1)

WARRANTS (Details 1)	9 Months Ended
	Dec. 31, 2017$ / sharesshares
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Warrants	13,663,014
Warrant One [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 1.2933
Class of Warrant or Right, Number of Warrants	5,873,289
Class Of Warrant Or Right Expiry Date	Feb. 26, 2019
Warrant Two [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 1.2933
Class of Warrant or Right, Number of Warrants	1,229,040
Class Of Warrant Or Right Expiry Date	Mar. 27, 2019
Warrant Three [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 1.2933
Class of Warrant or Right, Number of Warrants	328,166
Class Of Warrant Or Right Expiry Date	Mar. 31, 2019
Warrant Four [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 1.2933
Class of Warrant or Right, Number of Warrants	2,544,240
Class Of Warrant Or Right Expiry Date	Apr. 21, 2019
Warrant Five [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 1.2933
Class of Warrant or Right, Number of Warrants	1,201,164
Class Of Warrant Or Right Expiry Date	May 27, 2019
Warrant Six [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 1.2933
Class of Warrant or Right, Number of Warrants	1,173,370
Class Of Warrant Or Right Expiry Date	Jun. 30, 2019
Warrant Seven [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 0.7490
Class of Warrant or Right, Number of Warrants	1,313,745
Class Of Warrant Or Right Expiry Date	Feb. 26, 2019

WARRANTS (Details Textual)

WARRANTS (Details Textual) - USD ($)	9 Months Ended		12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Mar. 31, 2017	Mar. 31, 2016
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms	1 year 3 months 7 days		1 year 9 months 7 days
Number Of Warrants Exercised	5,000,172		262,045	148,787
Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price	$ (0.25)		$ 0.80	$ 0.80
Proceeds from Warrant Exercises	$ 1,125,038	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted				7,225,625
Adjustment To Additional Paid In Capital, Warrant Down Feature	$ 0
Warrants Issued	400,014
Class of Warrant or Right, Expiration Date	Jun. 27, 2020
$0.80
Class of Warrant or Right [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price	$ 0.749
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted	83,752
Warrant $0.80 | Scenario, Previously Reported [Member]
Class of Warrant or Right [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price	$ 0.80
$1.40
Class of Warrant or Right [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price	$ 1.2933
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted	941,191
Warrant $1.40 | Scenario, Previously Reported [Member]
Class of Warrant or Right [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price	$ 1.40
Common Shares [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, Upon Cashless Exercise Of Warrants			51,249	45,508
Number Of Warrants Exercised				148,787
Retained Earnings [Member]
Class of Warrant or Right [Line Items]
Adjustment To Additional Paid In Capital, Warrant Down Feature	$ 41,025
Warrant [Member]
Class of Warrant or Right [Line Items]
Proceeds from Warrant Exercises	$ 1,125,038
Warrant Solicitation [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.25

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Feb. 25, 2015	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Share-based Compensation		$ 271,001	$ 227,540	$ 1,284,257	$ 651,630
Common Shares [Member]
Stock Issued During Period, Shares, Issued for Services	262,904
Stock Transferred To Lenders	314,560
Stock Reimbursed To Officers	320,000
Stock Issued During Period, Value, Issued for Services	$ 241,185
Share-based Compensation	$ 210,323

RISK MANAGEMENT (Details Textua

RISK MANAGEMENT (Details Textual)	Dec. 31, 2017CAD
Maximum [Member]
Concentration Risk [Line Items]
Cash, FDIC Insured Amount	CAD 100,000

SUBSEQUENT EVENTS (Details Text

SUBSEQUENT EVENTS (Details Textual) - USD ($)	2 Months Ended
	Feb. 13, 2018	Dec. 31, 2017
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		1.50%
Subsequent Event [Member]
Subsequent Event [Line Items]
Proceeds from (Repayments of) Debt	$ 606,400
Subsequent Event [Member] | Short Term Loan [Member]
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	1.50%
Proceeds from Short-term Debt	$ 500,000
Debt Instrument, Maturity Date	Mar. 31, 2018
Subsequent Event [Member] | Employee Stock Option [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Description	The options will vest over three years - 1/3 on January 24, 2019, 1/3 on January 24, 2020 and 1/3 on January 24, 2021.
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	3,640,000
Shares Issued, Price Per Share	$ 0.155